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Phage Display on the Anti-infective Target 1-Deoxy-d-
xylulose-5-phosphate Synthase Leads to an Acceptor–
Substrate Competitive Peptidic Inhibitor
Alessio Marcozzi+,[a] Tiziana Masini+,[b] Di Zhu+,[b, c] Diego Pesce,[a] Boris Illarionov,[d]
Markus Fischer,[d] Andreas Herrmann,*[a] and Anna K. H. Hirsch*[b, c, e]
Introduction
Bacterial and protozoan infections are widely spread in some
human populations. The main burden of malaria and tubercu-
losis lies in resource-poor countries, for which, for example,
co-infection with human immunodeficiency virus (HIV) can
dramatically increase the mortality rate.[1,2] Moreover, in these
countries, drug compliance is often incomplete; this leads to
the emergence of drug-resistant strains of the pathogens,
against which most of the available drugs are no longer effec-
tive. Therefore, there is an urgent need for the discovery of
drugs with novel mechanisms of action that are able to over-
come the issue of drug resistance.[3]
The enzymes of the 2-C-methyl-d-erythritol-4-phosphate
(MEP, 1) pathway for the biosynthesis of the essential isopre-
noid precursors isopentenyl diphosphate (2) and dimethylallyl
diphosphate (3) have been studied over the past decade as
potential targets for the development of antimalarial and anti-
tuberculotic drugs (Scheme 1A).[4] The particular interest of
medicinal chemists in these enzymes arises from the fact that
the MEP pathway has been genetically validated as essential in
multiple organisms, including Mycobacterium tuberculosis[5] and
Plasmodium falciparum,[6] causative agents of tuberculosis and
malaria, respectively, but is absent in humans,[7, 8] who exclu-
sively utilize the alternative mevalonate pathway for the bio-
synthesis of 2 and 3.[9] This distinct taxonomic distribution sets
the stage for the development of selective drugs targeting the
enzymes of the MEP pathway.[10] An increasing number of
inhibitors for the enzymes of the MEP pathway have been
published, especially thanks to the growing number of crystal
and co-crystal structures deposited in the RCSB Protein Data
Bank,[11] with fosmidomycin—an inhibitor of the second
enzyme of the pathway IspC—being the most successful
example to date, given that it is the only inhibitor of the MEP
pathway that is being investigated clinically, in combination
with piperaquine.[12]
One of the least studied among the enzymes of the MEP
pathway is 1-deoxy-d-xylulose-5-phosphate synthase (DXS),
which catalyzes the first and rate-limiting steps of the MEP
pathway, consisting in the thiamine-diphosphate (ThDP)-de-
pendent decarboxylative condensation of pyruvate (4) and d-
glyceraldehyde-3-phosphate (5) to afford 1-deoxy-d-xylulose-5-
phosphate (6). Despite the high degree of sequence homology
of the ThDP-binding site of DXS with other human ThDP-
dependent enzymes [e.g. , transketolase (TK) or pyruvate dehy-
Enzymes of the 2-C-methyl-d-erythritol-4-phosphate pathway
for the biosynthesis of isoprenoid precursors are validated
drug targets. By performing phage display on 1-deoxy-d-xylu-
lose-5-phosphate synthase (DXS), which catalyzes the first step
of this pathway, we discovered several peptide hits and recog-
nized false-positive hits. The enriched peptide binder P12
emerged as a substrate (d-glyceraldehyde-3-phosphate)-com-
petitive inhibitor of Deinococcus radiodurans DXS. The results
indicate possible overlap of the cofactor- and acceptor-sub-
strate-binding pockets and provide inspiration for the design
of inhibitors of DXS with a unique and novel mechanism of in-
hibition.
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drogenase (PDH); for TK: 20% sequence identity overall, 47%
sequence identity in the ThDP-binding pocket between M. tu-
berculosis DXS and human TK],[13] DXS has distinctive features
compared to mammalian ThDP-dependent enzymes, from
both structural and kinetic points of view. In fact, together
with the peculiar domain arrangement, in which the particular-
ly big ThDP-binding site is located within the same mono-
mer,[14] DXS has a unique catalytic mechanism that involves the
formation of a ternary complex with substrates 4 and 5,[15]
whereas all other ThDP-dependent enzymes follow classical
ping-pong kinetics.[16] By taking advantage of these distinctive
features, selective inhibition of DXS over human ThDP-depen-
dent enzymes should be possible. The potential of DXS as a
drug target is also underlined by its involvement in pyridoxal
phosphate (vitamin B6)[17] and thiamine (vitamin B1)[18] biosyn-
thesis in many bacteria, offering the opportunity to target
three metabolic pathways at once. Furthermore, DXS possesses
an important regulatory role for the flux of metabolites
throughout the whole MEP pathway as shown recently.[19]
Considering its crucial importance in bacterial metabolism, it
is surprising that DXS is one of the least studied among the
enzymes of the MEP pathway in terms of crystallography and
inhibitor development. In fact, there are just two crystal struc-
tures deposited in the PDB of the enzyme in complex with its
cofactor ThDP (Escherichia coli, PDB ID: 2O1S, incomplete crys-
tal structure; Deinococcus radiodurans, PDB ID: 2O1X).[14] The
amino-acid residues lining the ThDP-binding pocket are highly
conserved among the DXS enzymes in different organisms
(e.g. , 68% sequence identity in the ThDP-binding pocket and
38% sequence identity overall between D. radiodurans and
M. tuberculosis DXS). However, striking differences in inhibitory
potency or affinity have been observed upon evaluating ThDP-
competitive inhibitors against distinct orthologues.[20] The
herbicide ketoclomazone, for which no information about the
mode of inhibition (MOI) is available, is known to weakly inhib-
it Chlamydomonas DXS (IC50=0.1 mm),
[21] whereas it is signifi-
cantly more potent against Haemophilus influenzae DXS (Ki=
23 mm).[22] Moreover, the number of inhibitors for DXS reported
in the literature to date (e.g. , 7–11, Scheme 1B) is very limited,
as is the structural information about the corresponding bind-
ing modes.[4, 22–26] Phosphonates such as 10 have been shown
to be pyruvate-competitive inhibitors, with Ki values in the low
micromolar range against M. tuberculosis DXS and remarkable
selectivity over mammalian ThDP-dependent enzymes.[25,26] We
recently reported fragment 11 to be a moderate inhibitor of
D. radiodurans DXS (IC50=595 mm) and validated its binding
mode in solution by using a combination of NMR spectroscopy
techniques.[13]
All the inhibitors for DXS reported in the literature so far are
small, organic molecules, but to our knowledge, there is no
report on peptidic inhibitors. Even though peptides still partial-
ly suffer from a “deficit in image”, most of the limits associated
with their development and optimization as therapeutic
agents have been overcome in the past decade. The fact that
peptides have several advantages over small organic molecules
encouraged medicinal chemists to reconsider their potential as
drug candidates. For example, the risk of systemic toxicity
associated with their administration is reduced, and thanks to
their short half-life, they do not tend to accumulate in tissues,
with a reduced risk of complications caused by their metabo-
lites.[27] In addition, they offer the advantage that they can be
effectively selected to bind functional sites of target enzymes
with high specificity.[28,29] Moreover, multiple peptides can be
used to target different parts of the same enzyme, thus lead-
Scheme 1. Overview of the MEP pathway. A) 2-C-methyl-d-erythritol-4-phosphate (MEP, 1) pathway for the synthesis of isopentenyl diphosphate (2) and di-
methylallyl diphosphate (3), universal precursors for the biosynthesis of isoprenoids. B) Selection of known inhibitors of DXS (7–11).
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ing to a decrease in activity by binding to the active or allo-
steric regulatory sites or by altering its surface properties.[30,31]
Similar with other ThDP-dependent enzymes,[32,33] binding of
ThDP with DXS is very tight (Kd=0.114 mm for Deinococcus ra-
diodurans ; Kd=3.1 mm for M. tuberculosis).
[13] The large active
site and high binding affinity for ThDP make it attractive to de-
velop ThDP-competitive peptidic inhibitors.
Combinatorial peptide libraries have been used as a source
of ligands for a variety of macromolecules, and different meth-
ods are known to select high-affinity binders from such libra-
ries. One of the most efficient and cost-effective methods to
select peptide binders is phage display (Figure S1 in the Sup-
porting Information).[34] By using this technique, random
peptides can be expressed on the surface of a bacteriophage
leading to libraries with a complexity of up to 109 different
peptides, which are subjected to several rounds of selection by
which only target-bound phages are retained. The use of
phage display allows large libraries of potential inhibitors to be
screened without the need for a classical high-throughput
screening (HTS) campaign or chemical synthesis of large libra-
ries.
Results and Discussion
To identify peptidic inhibitors for DXS, we chose to exploit
phage display by using the model enzyme D. radiodurans DXS,
given that it is more stable than M. tuberculosis DXS.
We checked the stability of D. radiodurans DXS both at 4 8C
and at room temperature by monitoring its activity for up to
37 h by using IspC as an auxiliary enzyme, which enables spec-
trophotometric monitoring of the consumption of NADPH. No
loss in activity was observed even after 37 h at room tempera-
ture. From these initial tests, we concluded that D. radiodurans
DXS was stable enough to be used as a target during the
phage-display process. To rule out that we select for support
binders, we designed a phage-display protocol for which the
phages were incubated in solution with DXS, and DXS was
subsequently recovered by affinity purification by using mag-
netic beads. We used a two-step selection approach to identify
peptide binders (Table 1). During the first step, we screened a
fully random M13 bacteriophage peptide library to detect spe-
cific sequences that are able to bind any part of the surface of
DXS. During this step, we used two types of magnetic beads
and several elution buffers to avoid background-selection bias
(Figure S2). Analysis of the selected peptides enabled us to
design a new and more stringent library for the second selec-
tion step, in which we screened for sequences that could spe-
cifically bind to the ThDP-binding site of DXS. We used a solu-
tion of ThDP as competitive eluent to select only phages that
interact at the ThDP-binding site. Given that unspecific binders
are often present after the second round of selection, we
added wild-type M13 phages as competitors: wild-type phages
efficiently compete with virus particles expressing the peptide
library for unspecific phage-target interactions, and they can
be easily filtered out during postsequencing analysis. Both
measures decrease the probability of selecting unspecific bind-
ers or false positives.
We used a commercially available M13 library PhD12 (NEB
E8111L) for the first phage-display selection against DXS. After
three rounds of selection, the analysis of the sequences clearly
showed that a true selection had occurred: several sequences
were repeated multiple times; this indicated their enrichment
in the population (Table 2). Moreover, we observed an increase
in the phage titer during the selection. Even though no clear
motif emerged, we decided to test the most recurrent pep-
tides to investigate their effect on DXS.
We took the four most prevalent sequences (i.e. , P1–P4,
Table 2) and tested the synthesized peptides for their inhibito-
Table 2. List of amino-acid sequences obtained after the first round of
phage display.
Sequence ID[a] Sequence[b] Peptide ID[c,d]
07AJ42 VNHEYKLHSIKY






07AJ60 MSSRSRPHINSL P3 (V3)
07AJ61 QLARMSSLHVPM















[a] Sequencing file identification number. [b] Peptide sequences were
generated by translating the sequenced DNA considering the “amber
mutation” codon usage, that is, the codon TAG was translated with the
amino acid Gln. [c] Peptide IDs (P1, P2, P3, P4) are assigned to every
sequence tested. [d] The value in brackets corresponds to the number of
times the sequence was found to be repeated.
Table 1. Overview of the two phage-display protocols used for the first
and second selections.
Phage display I Phage display II
library X12GGGS XSSX9GGGS
competitors none wild-type M13
Rounds I and II
target desthiobiotin-DXS His-tag-DXS
solid support streptavidin-coated beads nickel-coated beads
eluent biotin ThDP
Round III
target His-tag-DXS not performed
solid support nickel-coated beads not performed
eluent imidazole not performed
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ry activity against D. radiodurans DXS. The peptides were dis-
solved in DMSO (for P1 and P2) or water (for P3 and P4) and
their inhibitory activities against D. radiodurans DXS were
tested by using a coupled assay with E. coli IspC as the auxili-
ary enzyme by monitoring the disappearance of NADPH spec-
trophotometrically at l=340 nm.[29] So as not to miss out on
potential slow binders, we investigated the influence of incu-
bating the peptides with D. radiodurans DXS in Tris·HCl buffer
(pH 7.6) for 30 h both at room temperature and at 4 8C. Given
that the activity of the enzyme was unchanged in the presence
of up to 3% of DMSO, we performed both the direct measure-
ments and the incubation studies with 2.5% of DMSO.
We noticed that the peptides dissolved in DMSO gave
better results if incubated at 4 8C, whereas peptides dissolved
in water showed the maximum inhibition at room tempera-
ture. The best results were obtained for P2 (50% inhibition at
1000 mm after incubation at 4 8C for 30 hours) and particularly
P3 (47% inhibition at 250 mm after incubation at room temper-
ature for 30 h; Table 4). Both P2 and P3 contain two adjacent
Ser residues in the sequence: this Ser–Ser motif might function
as a fingerprint for the recognition of the ThDP-binding pocket
of D. radiodurans DXS. We performed a second round of phage
display selection protocol by adding a custom-made library
taking into account the Ser–Ser motif (see the Experimental
Section for further details). After the selection, the eluted
phages were sequenced, and the results are shown in Table 3.
The list contains some sequences that were not present in the
commercial library PhD12, such as A10, A06, A01, and D02,
whereas A10 is a non-specific protein binder that we found
several times in other displays.[35] A06 was repeated several
times but did not have a Ser–Ser motif. The last two sequences
(A01 and D02) might be contaminants given that they were
not repeated. Again, the selection did not result in the emer-
gence of a particular motif, but rather in the enrichment of
specific amino acids with some sequences occurring multiple
times. As an example, P9 was found several times, whereas
others were not repeated but contained some recurring motifs
such as the presence of additional Ser residues and multiple
aromatic amino acids within the sequence (marked in bold
and underlined in Table 3). Moreover, we observed that all the
peptides contained at least one Pro residue, preferentially in
the central part of the sequence, and a Leu or Ile residue,
which might play a role in defining conformational preferen-
ces.
For ThDP-dependent enzymes such as TK, the binding pock-
ets of ThDP and the acceptor substrate are often in proximity
and even share some key amino acids[36–42] (Figure S3). This
might also apply to DXS and its acceptor substrate, d-glyceral-
dehyde-3-phosphate (d-GAP). To identify both substrate- and
cofactor-competitive inhibitors during screening, the concen-
trations of both ThDP and d-GAP should be adjusted accord-
ingly upon evaluation of the inhibitory activity. D. radiodurans
DXS does not afford satisfactory data quality under low con-
centrations of both d-GAP and ThDP. Thus, we proposed two
rounds of activity evaluation, with assay conditions I and assay
conditions II aimed at identifying ThDP- and d-GAP-competi-
tive inhibitors, respectively (Table 4). We omitted preincubation
upon screening for d-GAP-competitive inhibitors, as binding of
this substrate is neither tight nor irreversible. The results of
two rounds of activity evaluation of P5–P12 against D. radio-
durans DXS are summarized in Table 4. Peptide P13 from the
first phage display also contains the Ser–Ser motif ; therefore,
we tested its activity even though the sequence was not en-
riched.
During the inhibitory evaluation with assay conditions I, P7
showed an IC50 value of (13:3) mm, and P13 emerged as a
double-digit micromolar inhibitor of D. radiodurans DXS [IC50=
(49:11) mm] after incubation at 4 8C for 30 hours. The other
peptides did not show any inhibition or only very weak inhibi-
tory activity (e.g. , P10, 20% inhibition at 1000 mm). We deter-
mined the accurate concentration of P7 in solution by UV
spectrophotometry by taking advantage of the fact that P7
contains a single Trp residue. As a consequence, the IC50 value
was recalculated to (9.5:2.0) mm. Unfortunately, it was not
possible to determine the accurate concentration of P13 in
solution by absorbance measurements owing to the absence
of Trp or Tyr residues in the amino-acid sequence.
As for activity evaluation with assay conditions II, P12, the
peptide found in eight phage clones after the second round of
phage display, has an IC50 value of (461:25) mm. The differ-
ence in IC50 values under the two screening conditions could
be an indication that P12 might be d-GAP-competitive. Pep-
tide P7 has an increased IC50 value of (86:13) mm ; this indi-
cates it might be ThDP competitive. Peptide P13 did not ex-
hibit any activity with assay conditions II, which suggests that
it might indeed be slow binding and ThDP competitive or that
preincubation might determine its activity.
The use of a coupled spectrophotometric assay requires a
follow-up assay with the auxiliary enzyme IspC. Therefore, we
Table 3. Peptide sequences obtained after the round of second phage
display.

















[a] Peptide sequences were generated by translating the sequenced DNA
considering the “amber mutation” codon usage, that is, the codon TAG
was translated with the amino acid Gln. [b] Extra Ser residues and aro-
matic residues are in bold and underlined. [c] The value in brackets corre-
sponds to the number of times the sequence was found to be repeated.
[d] Indicates a contaminant sequence that nonspecifically recognizes any
protein.
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tested P7 for its inhibitory potency against E. coli IspC and
found that it has an IC50 value of (490:60) mm. Peptide P13 is
not active against E. coli IspC without preincubation but shows
an IC50 value of (266:42) mm after preincubation. Peptide P12
is not active against IspC.
Although DXS and IspC catalyze the first two reactions of
the MEP pathway, their structures and functions are very differ-
ent. The fact that P7 and P13 inhibits both enzymes raised our
concern of nonspecific inhibition. To eliminate false-positive
peptides before the MOI study, we performed a detergent
assay, which is commonly used to confirm small-molecule ag-
gregators.[43,44]
In parallel, given that inhibition arising from aggregation de-
pends on the amount of enzyme, we compared the inhibitory
activity at different DXS concentrations (Table 5).[45] The results
demonstrate that the addition of a small amount of detergent
or an increase in the concentration of DXS led to significant at-
tenuation of inhibitory activity for P7 and P13, whereas P12
was not affected. To corroborate this result, solutions of P7
and P13 in assay buffer were investigated by transmission
electron microscopy (TEM), and the formation of fibers was ob-
served (Figure S4). Taken together, three independent experi-
ments showed that P7 and P13 are nonspecific inhibitors that
inhibited DXS and IspC by aggregating into fibers and seques-
tering the enzyme.[46] Even though we used low-binding tubes
during phage display and 0.05% Tween 20 in the washing
buffer, it might not have been sufficient to exclude all of the
false positives. Here, we showed that such fiber-forming non-
specific inhibitors could be conveniently identified by adding
0.01% Triton X-100 to the assay buffer. To the best of our
knowledge, we report here for the first time the application of
the detergent assay on peptidic inhibitors. Peptide P12 was
confirmed as a true inhibitor against D. radiodurans DXS.
As it is not active against IspC, its MOI could be studied with
the coupled assay. For substrate-competitive inhibitors, the
Cheng–Prusoff Equation (1) holds:[47]




in which [S] represents the concentration of the corresponding
substrate, and Km is the Michaelis–Menten constant in the
absence of the inhibitor. By varying the initial substrate con-
centration and plotting IC50 against (1+ [S]/Km), a competitive
inhibitor should generate a straight line passing through the
origin, with the slope equivalent to the inhibition constant,
Ki.
[48,49] The MOI study of P12 competing with d-GAP is shown
in Figure 1.
The results of cofactor and pyruvate competition are shown
in Figure S5.
The full kinetic characterization revealed that P12 is a d-
GAP-competitive inhibitor, with Ki= (113:4) mm, and noncom-
petitive with respect to both the cofactor ThDP and the donor
substrate pyruvate.
Table 4. List of peptides selected from the first and second phage dis-
plays and their inhibitory activities against D. radiodurans DXS, both in
direct measurements and after incubation.
First round of phage display
Peptide ID[a] Solvent[h] Inhibition [%][b]
P1 DMSO 30 (at 1000 mm)[c]
P2 DMSO 50 (at 1000 mm)[c]
P3 H2O 47 (at 250 mm)
[c]
P4 H2O 30 (at 1000 mm)
[c]
Second round of phage display: Assay conditions I[e]
Peptide ID[a] Solvent[h] IC50 [mm]
P5 DMSO >1000
P6 DMSO >1000

















[a] P1–P4 are amidated at the C terminus; peptides P5–P13 are not ami-
dated at the C terminus. [b] Percentage inhibition and IC50 values were
determined by using a spectrophotometric assay. Full details of the bio-
chemical assay conditions are provided in the Experimental Section. The
values reported in the table correspond to the maximum concentration
of the peptide soluble in the assay conditions. [c] Percentage of inhibition
or IC50 values obtained after preincubation of the peptide in Tris·HCl
buffer (pH 7.6) with D. radiodurans DXS for 30 h at room temperature
and/or at 4 8C. [d] The value in parentheses corresponds to the recalculat-
ed IC50 value on the basis of the concentration of the peptide determined
by absorbance, as described in the Experimental Section. [e] Activity eval-
uation with assay conditions I aimed at screening for ThDP competitive
inhibitors, with 1.2 mm of ThDP, 10VKm (ThDP), and 0.5 mm of d-GAP, 15V
Km (d-GAP). [f] Activity evaluation with assay conditions II aimed at
screening for d-GAP competitive inhibitors, with 0.1 mm of ThDP, 0.1 mm
of d-GAP, 3VKm (d-GAP). [g] Preincubation was not performed in this
round of evaluation, as substrate binding of DXS was considered to be
neither tight nor irreversible. [h] DMSO concentration was 3%.
Table 5. Results of the detergent assay and DXS concentration depend-
ence to identify false positives.
Addition of detergent DXS conc. [mm] IC50 [mm]
P7[a] – 0.4 13:3
0.01% Triton X-100 0.4 >1000
– 1.0 >1000
P13[a,c] – 0.4 49:11
0.01% Triton X-100[d] 0.4 >1000
– 1.0 547:88
P12[b] – 0.4 461:25
0.01% Triton X-100 0.4 449:33
1.0 472:16
[a] Assay conditions I were used for P7 and P13. [b] IC50 of P12 was deter-
mined with assay conditions II. [c] Preincubation was performed in all
three assays of P13. [d] For P13, detergent was added after preincuba-
tion.
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As P12 was washed out using a ThDP buffer, this result vali-
dated our previous hypothesis : for DXS, and some other ThDP-
dependent enzymes, the binding pockets of ThDP and the ac-
ceptor substrate are closely related, both structurally and func-
tionally, and may not be considered completely separately.
Different from our expectations, we did not identify any
ThDP-competitive peptidic inhibitor during the second round
of phage display. A possible reason might be that the stringent
phage library coincidentally did not contain any hits. Further-
more, the polar character of the diphosphate-binding pocket
together with the possibility for metal chelation make the
identification of ThDP-competitive inhibitors through phage
display challenging.
Conclusions
Herein, we reported the discovery of a d-GAP-competitive pep-
tidic inhibitor, P12, with a Ki value of (113:4) mm, by phage
display targeting the thiamine diphosphate (ThDP)-binding
pocket. The expected ThDP-competitive inhibitors were con-
firmed to be nonspecific false positives by using the detergent
assay and transmission electron microscopy. Similar to what
was found for other ThDP-dependent enzymes, our results in-
dicate that the cofactor- and acceptor-substrate-binding pock-
ets are closely related both structurally and functionally. This
property might provide inspiration to design novel inhibitors
for 1-deoxy-d-xylulose-5-phosphate synthase (DXS), targeting
the key amino acids shared by the ThDP- and d-GAP-binding
pockets. Peptide P12 is the first known peptidic inhibitor of
DXS and sets the stage for further rounds of optimization.
Experimental Section
Bacterial strain: E. coli ER2738 (NEB E4104S) [Genotype: F’proA+B+
lacIq D(lacZ)M15 zzf::Tn10(TetR)/ fhuA2 glnV D(lac-proAB) thi-1
D(hsdS-mcrB)5] is a male E. coli in which F’ can be selected for by
using tetracycline, and it allows Blue/White screening and is an
amber mutant strain. It was used for cloning and expression of the
phage library, for titering, and for inoculation of the sequencing
plates.
Phage display I: The first phage-display selection protocol was
performed by using the commercially available M13 library PhD12
(NEB E8111L) consisting of M13 phages expressing a 12aa peptide
at the N terminus of each coat protein p3, and a small Gly–Gly–
Gly–Ser linker was inserted between the peptide and the coat pro-
tein to increase the conformational freedom of the exposed pep-
tides and to minimize the contribution of the protein p3 to the
overall binding. The schematic sequence of this library is N-term-
X12-GGGS-p3-C-term. Three rounds of selection were performed in
phosphate-buffered saline (PBS; 1 mL, sodium phosphate 50 mm,
NaCl 150 mm, pH 7.5) incubating 10E10 phages with D. radiodurans
DXS (1 mg) in a 2 mL protein-low-binding tube for 30 min on ice.
For the first two rounds, DXS functionalized with N-hydroxysuccini-
mide (NHS)–desthiobiotin and Dynabeads MyOne Streptavidin C1
(Invitrogen 65001) were used to capture DXS from the solution.
For the third round, to avoid selection of phages against streptavi-
din and given that D. radiodurans DXS contains an N-terminal His-
tag, MagneHis Ni Particles (Promega V8560) were used as captur-
ing system. After the incubation step, 0.1 mL of beads were added
to the solution, which was mixed in a thermo shaker at 4 8C for
15 min. The tube was placed in a magnetic rack to allow for adhe-
sion of the magnetic beads on one side of the tube. Phages ex-
pressing DXS binders were retained on the bead surface, and the
buffer containing unbound phages was gently discarded from the
tube. To remove weakly bound phages further, the beads were
washed with PBST (10V1 mL PBS with 0.05% Tween 20) whilst re-
taining them using a magnetic rack. The elution of strongly bound
phages from the beads was achieved by suspending the beads in
the elution buffer (1 mL, 1 mm Biotin in PBS for rounds 1 and 2
and 500 mm imidazole in PBS for round 3). After separation of the
beads, the solution containing the eluted phages was used to am-
plify the selected pool of phages by infecting a fresh culture of
E. coli ER2738. Infection, production, and purification of the phages
were performed by following the manufacturer’s manual. Peptides
P1–P4 were purchased from CASLO (Lyngby, Denmark) with purity
>97% according to HPLC.
Library design and cloning: A custom-made library was designed
to include the motif Ser–Ser at the N terminus of the peptide
library. Two oligomers, one coding for the library itself and one
used for cloning purposes were designed:
Library oligo: CATGT TTCGG CCGA(MNN)9 GGAGG AMNNA GAGTG
AGAAT AGAAA GGTAC CCGGG
Extension primer: CATGC CCGGG TACCT TTCTA TTCTC
The “library primer” codes for the reverse strand of the library, and
it includes two flanking regions that contain the restriction site for
KpnI/Acc651 and EagI needed for cloning into the M13KE vector.
The random part of the peptide sequence is coded by NNK codons
(reverse complement of MNN), for which N is any of the bases,
whereas K represents G or T (thus, M represents C or A). An NNK
codon can encode for all 20 amino acids but only for one stop-
codon: TAG. Combining the use of NNK codons with amber
mutant strains such as E. coli ER2738 ensures that the whole library
will code for full-length peptides. The “extension primer” is partially
complementary with the library-coding oligomer, and it was used
to generate the double-stranded DNA needed for cloning. The
preparations of the library duplex and the cloning were performed
as indicated in the manufacturer’s manual (NEB E8111L).
Phage display II : Two rounds of selection were performed by
using a custom-made phage library. The schematic sequence of
the expressed library is : N-term-XSSX9-GGGS-p3-C-term. TBS (tris-
buffered saline, 50 mm Tris·HCl pH 7.5, 150 mm NaCl) was used as
incubation buffer, TBST (TBS with 0.05% Tween 20) was used as
washing buffer, MagneHis Ni Particles (Promega V8560) were em-
ployed for protein recovery, and 1 mm ThDP in TBS was used as
Figure 1. Mode-of-inhibition study of P12. Peptide P12 is competitive with
acceptor-substrate d-GAP, as illustrated by linearity between the XY series.
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elution buffer. ThDP was chosen as competitive eluent to elute
peptides specifically interacting with the ThDP-binding site of DXS.
The same procedure as described for phage display I was used
with the following modifications: DXS (1 mg) was incubated simul-
taneously with phages from the new library, phages from the origi-
nal PhD-12 library were added to increase sequence complexity,
and wild-type phages were supplemented to screen for nonspecif-
ic binders. The different phage pools were mixed in a 1:1:1 ratio
prior to incubation with the target.
Sequencing: The last elution fractions from the phage display ex-
periments were serially diluted (1:10) and used to infect a fresh cul-
ture of E. coli ER2738. The infected culture was plated on lysogeny
broth (LB)–agar supplemented with tetracycline, isopropyl b-d-1-
thiogalactopyranoside (IPTG), and XGal. Blue colonies resulting
from phage infection were picked and sent for Sanger sequencing
(at GATC Biotech) by using a custom-designed M13-specific se-
quencing primer (GTACA AACTA CAACG CCTGT). Peptides P5–P13
and P7a–P7 l were purchased from ProteoGenix SAS (Schiltigheim,
France) with purity >95% according to HPLC.
Gene expression and protein purification of D. radiodurans DXS:
Gene expression and protein purification of D. radiodurans DXS
were performed as reported in the literature.[13]
Spectrophotometric assay for determination of IC50 values
against D. radiodurans DXS (assay conditions I): Direct measure-
ments of the inhibitory activities with the spectrophotometric
assay were performed as reported previously.[13] The tolerance of
DXS with respect to DMSO concentration was determined by mea-
surement of the reaction velocity in the presence of different con-
centrations of DMSO. The activity of the enzyme was found to be
stable in the presence of up to 3% DMSO. To determine the inhibi-
tory activity of the peptides after incubation, several solutions
were prepared containing degassed Tris·HCl (pH 7.6, 100 mm.
300 mL), D. radiodurans DXS (0.79 mm), and different concentrations
of each peptide with a dilution factor of 1:2 starting, if possible,
from 1000 mm. The solutions were incubated at room temperature
or at 4 8C for 30 h. Preliminary control experiments showed that
the activity of D. radiodurans DXS was unchanged at room temper-
ature or at 4 8C after 30 h. After the incubation time, each incubat-
ed solution (95 mL) was transferred to a 96-well plate, and a buffer
containing Tris·HCl (pH 7.6, 100 mm) and d-glyceraldehyde-3-phos-
phate (4.0 mm) was added (47.5 mL). The reaction was started by
the addition of a buffer solution (47.5 mL) containing Tris·HCl
(pH 7.6, 100 mm), MnCl2 (16 mm), dithiothreitol (DTT, 20 mm),
NADPH (2.0 mm), sodium pyruvate (2.0 mm), ThDP (4.89 mm), and
E. coli IspC (8.2 mm). A control experiment with the enzyme incu-
bated in Tris·HCl buffer (and DMSO if testing peptides as stock sol-
utions in DMSO) at the same temperature and for the same time
was performed in parallel to monitor for potential loss in activity
of the enzyme itself, which has never been observed. The reaction
was monitored photometrically at room temperature at l=
340 nm by using a Synergy Mx (Biotek) microplate reader. Absorb-
ance readings were taken every 30 s.
Spectrophotometric assay for determination of IC50 values
against D. radiodurans DXS (assay conditions II): Photometric
assays were conducted in transparent flat-bottomed 384-well
plates (Nunc MaxiSorp). Assay mixtures contained Tris·HCl
(100 mm, pH 7.6), 4 mm MnCl2, dithiothreitol (DTT; 2 mm), 0.5 mm
NADPH, 15 mm ThDP, 1.0 mm sodium pyruvate, 0.1 mm glyceralde-
hyde-3-phosphate, 8.3 mm E. coli IspC, 0.4 mm D. radiodurans DXS,
and 3% DMSO. Buffer A contained Tris·HCl (100 mm, pH 7.6), 8 mm
MnCl2, DTT (4 mm), 1 mm NADPH, and 30 mm ThDP. Buffer B con-
tained Tris·HCl (100 mm, pH 7.6), 2.0 mm sodium pyruvate, and
0.2 mm glyceraldehyde-3-phosphate. The dilution series was per-
formed in DMSO (2.4 mL) in each well, starting with a 80 mm DMSO
stock solution of P12 and covered the concentration range of 2000
to 2.0 mm. The reaction was started by adding buffer A (30 mL) to
buffer B (30 mL). The reaction was monitored photometrically at
room temperature at l=340 nm by using a Synergy H1 (Biotek)
microplate reader. Initial rate values were evaluated with a nonlin-
ear regression method by using the program Dynafit.[50]
MOI study: Photometric assays were conducted in transparent
flat-bottomed 384-well plates (Nunc MaxiSorp). Michaelis–Menten
constants of cofactor and both substrates were determined with a
previously reported method.[48,49] IC50 values were determined
under assay conditions II, with variation of cofactor and substrates,
respectively. The result was repeated in duplicate. The Ki value was
calculated with SigmaPlot 13.
Gene expression, purification of E. coli IspC, and biochemical
evaluation of inhibitory activity against E. coli IspC by spectro-
photometric assay: Gene expression and purification of E. coli IspC
were performed according to a literature procedure.[51] 1-Deoxy-d-
xylulose-5-phosphate reductoisomerase (IspC) of E. coli bearing a
His6-tag at its N-terminal end was produced in and purified from
recombinant E. coli strain M15 pQEYAEM. Cells were grown in LB
medium in a shaker at 37 8C supplied with ampicillin (100 mgmL@1)
until the OD600 value reached 0.4. Thereafter, IPTG was added to a
final concentration of 1 mm, and the cell suspension was incubated
further at 30 8C with vigorous agitation for 16 h. Thereafter, cells
were harvested by centrifugation, washed once with 0.9% NaCl
solution, and frozen at @20 8C for storage.
For DXR purification, cell paste (5 g) was resuspended in Tris hy-
drochloride buffer (25 mL, 50 mm, pH 8.0), NaCl (300 mm), 0.02%
NaN3, and 15% imidazole and disrupted in French Press; cell debris
was centrifuged down, and the supernatant was placed on the top
of a Ni-NTA column (1V10 cm). After unbound proteins were
washed from the column with the same buffer, the column was
developed with an imidazole gradient (15–800 mm). Eluent frac-
tions containing DXS were identified with SDS-polyacrylamide gel
electrophoresis, combined, dialyzed versus Tris hydrochloride
(30 mm, pH 8.0), 30 mm NaCl, 1 mm DTT, and 0.02% NaN3 and con-
centrated by ultrafiltration and frozen at @80 8C for storage.
Spectrophotometric assay for determination of IC50 values
against E. coli IspC: Biochemical evaluation of the inhibitory activi-
ty of P7 against E. coli IspC was performed according to a protocol
reported in the literature.[52] Spectrophotometric inhibition assays
with E. coli IspC were performed in 384-well plates with a flat trans-
parent bottom. Assay mixtures (total volume: 60 mL) contained
Tris hydrochloride (100 mm, pH 7.6), 4 mm MnCl2, 5 mm DTT,
0.5 mm NADPH, 5% DMSO, 30 nm of recombinant IspC protein,
and tested compound. Dilution series (1:3) of potential inhibitors
covered the concentration range of 200 to 0.2 mm. The reaction
was started by the addition of 1-deoxyxylulose-5-phosphate (DXP)
to a final concentration of 0.5 mm. The reaction was monitored
photometrically (l=340 nm) at room temperature (20–23 8C) in a
microplate reader (SpectraMax M5, Molecular Devices, USA). Initial
rate values were evaluated by using the nonlinear regression
method with the program Dynafit.[50]
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